The novelty of bupropion as a dopaminergic antidepressant for the treatment of adult attention deficit hyperactive disorder.


Abstract

Attention deficit hyperactive disorder (ADHD), a hyperactivity disorder that is prevalent among children may continue as an adulthood attention deficit. To date, treating an individual with an adult ADHD may be an arduous task as it involved numerous challenges, such as a need for high index of suspicion to diagnose this medical condition. Many psychiatric disorders masquerade as ADHD and delayed the necessary assessment and proper treatment for the debilitating medical condition. Adult ADHD would also be misdiagnosed (or under-diagnosed) due to the facts that this medical condition is being masked by his or her high level of intellectuality achievement. As the ADHD in adult persisted, it may end up with impairment in the personal-social-occupational function, in which the management became a great challenge. The treatment of ADHD can be optimized by using various drugs targets agents like a norepinephrine-dopamine reuptake inhibitor (NDRI), with or without psychostimulants like methylphenidate, which was marketed as Ritalin. Bupropion, an NDRI has a novel effect on ADHD as the molecule exerts its effects by modulating the reward-pleasure mesolimbic dopaminergic system, and at the same time regulating the elevating mood dimension of the noradrenergic neurotransmission. The role of bupropion in the neural and psychopharmacological perspective treatment of ADHD was deliberated. This review highlights the novelty effects of bupropion in treating ADHD, together with the help of other successful bio-psycho-social measures, which may offer a great assistance to the psychiatrists in treating their patients to the level best.